India probes Roche over biosimilars
Mylan and Biocon claim Roche abused its market dominance to quash generic breast cancer antibodies
India’s Competition Commission has ordered an investigation into Swiss pharma major Roche for allegedly using its dominant position to block entry of low-cost alternatives of breast cancer antibody trastuzumab (marketed under various names, including Herceptin).